** Shares of Aroa Biosurgery ARX.AX rise 14.9% to A$0.540, their highest levels since February 27

** Stock set for its strongest session since October 22, 2024 - if current trends hold

** The soft-tissue regeneration products maker posts normalised FY EBITDA profit of NZ$4.2 million ($2.50 million) compared to an EBITDA loss NZ$3.1 million last year

** Co sees FY26 normalised EBITDA of NZ$5 million - NZ$8 million

** Stock on track for fifth consecutive session of gains, if current trends hold

** Stock down 29.9% YTD, including current session's moves

($1 = 1.6787 New Zealand dollars)

(Reporting by Manasi Dasa in Bengaluru)

((Manasi.DasaSundeep@thomsonreuters.com;))